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ABSTRACT
Family history, a well-established risk factor for breast cancer, can have both genetic and environmental
contributions. Shared environment in families as well as epigenetic changes that also may be influenced
by shared genetics and environment may also explain familial clustering of cancers. Epigenetic regulation,
such as DNA methylation, can change the activity of a DNA segment without a change in the sequence;
environmental exposures experienced across the life course can induce such changes. However, genetic-
epigenetic interactions, detected as methylation quantitative trait loci (mQTLs; a.k.a. meQTLs) and
haplotype-dependent allele-specific methylation (hap-ASM), can also contribute to inter-individual
differences in DNA methylation patterns. To identify differentially methylated regions (DMRs) associated
with breast cancer susceptibility, we examined differences in white blood cell DNA methylation in 29
candidate genes in 426 girls (ages 6–13 years) from the LEGACY Girls Study, 239 with and 187 without a
breast cancer family history (BCFH). We measured methylation by targeted massively parallel bisulfite
sequencing (bis-seq) and observed BCFH DMRs in two genes: ESR1 (D4.9%, P = 0.003) and SEC16B (D3.6%,
P = 0.026), each of which has been previously implicated in breast cancer susceptibility and pubertal
development. These DMRs showed high inter-individual variability in methylation, suggesting the
presence of mQTLs/hap-ASM. Using single nucleotide polymorphisms data in the bis-seq amplicon, we
found strong hap-ASM in SEC16B (with allele specific-differences ranging from 42% to 74%). These
findings suggest that differential methylation in genes relevant to breast cancer susceptibility may be
present early in life, and that inherited genetic factors underlie some of these epigenetic differences.
Abbreviations: BCA: breast cancer; BCFH: breast cancer family history; bis-seq: bisulfite sequencing;
BMI: body mass index; DMR: differentially methylated regions; EWAS: epigenome-wide association study;
GWAS: genome-wide association study; hap-ASM: haplotype-dependent allele-specific methylation;
LD: linkage disequilibrium; LEGACY: Lessons in Epidemiology and Genetics of Adult Cancer from Youth;
mQTL: methylation quantitative trait loci; SNPs: single nucleotide polymorphisms; WBC: white blood cells
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Introduction
Family history is a well-established risk factor for breast cancer
(BCA) [1], increasing risk 2- to 4-fold, depending on the num-
ber of affected 1st- and 2nd-degree relatives and their ages at
diagnosis [1]. Three classes of BCA susceptibility genes—high,
intermediate, and low—exhibit different levels of risk and prev-
alence in the general population (reviewed in [2]): pathogenic
variants in high-risk genes, including BRCA1, BRCA2, PTEN,
and TP53, are relatively rare and explain about 20% of the pro-
portion of the genetic variance in risk, whereas pathogenic
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variants in intermediate-risk genes, including ATM, BRIP1,
CHEK2, and PALB2, explain a further 3% of the heritability of
the disease. More recently, »100 common, low-risk single
nucleotide polymorphisms (SNPs) have been associated with
BCA risk through genome-wide association studies (GWAS)
and explain an estimated 16–20% of heritability [3]. The
remaining familial clustering is likely driven by shared environ-
ment as well as epigenetic changes that may be influenced by
both genetics and shared environment.
Epigenetic regulation, such as DNA methylation of BCA-
associated genes [4–6], can change the activity of a DNA seg-
ment without changing the underlying DNA sequence and can
be altered throughout life (reviewed in [7,8]). DNA methyla-
tion, occurs mostly at cytosine residues in CpG dinucleotides
and has an important role in regulating gene expression and
tumorigenesis [6]. DNA methylation alterations in BRCA1
have been observed in BCA tissues [4,5], and modest case-con-
trol differences in BRCA1 methylation of white blood cells
(WBCs) have also been reported [9,10]. In addition, several epi-
genome-wide association studies (EWAS) using WBCs have
found that low average epigenome-wide methylation was asso-
ciated with higher risk of BCA [11,12]. In addition, Xu et al.
have reported that a specific CpG methylation signature using
WBC DNA improves risk prediction for BCA [13]. In addition
to environmental factors modifying DNA methylation, a subset
of CpG sites have strong associations with SNPs in cis [14–16],
suggesting that DNA methylation alterations can be driven by
genetic differences. Haplotype-dependent allele-specific DNA
methylation (hap-ASM) is the physical counterpart of such
mQTLs [14–18]. Thus, to accurately identify environmental
effects on epigenetic alterations, it is critical to identify the extent
that mQTLs and hap-ASM drive epigenetic differences across
individuals. In addition, disease associations involving mQTLs
and/or hap-ASM can provide useful insights to genetic risk [17].
Distinct from genomic imprinting, where the methylation of
an allele is determined by its parent-of-origin, for loci with
hap-ASM the local sequence context (haplotype) acts in cis to
dictate the methylation status of local CpGs. Loci that show
hap-ASM can be identified by bisulfite sequencing (bis-seq), in
heterozygotes, if SNPs are present in the bis-seq amplicons.
The closely related term mQTL (strictly, cis-mQTL) refers to
loci in which the CpG methylation levels, which are typically
scored in case series by microarray-based methods such as Illu-
mina Methylation BeadChips, correlate strongly with genotypes
at nearby SNPs, as assessed by SNP genotyping in the same
series of individuals. Hap-ASM loci and mQTLs in linkage dis-
equilibrium (LD) with disease associated SNPs from GWAS
can translate into modest but important methylation differen-
ces between low- and high-risk populations. From a cautionary
standpoint, reviews of EWAS design have discussed the poten-
tial pitfall of falsely concluding that epigenetic changes are due
to environmental pathways or disease progression, rather than
genetic differences between cases and controls [19]. At the
same time, the finding of hap-ASM in a haplotype block that
also contains a relevant GWAS peak can be useful for providing
biological support for that statistical peak, and for localizing
regulatory DNA sequences within the haplotype block, which
reveal themselves by conferring the physical asymmetry in
methylation between the two alleles [17,18].
Measuring methylation in repetitive elements in WBC DNA,
we previously found lower levels in young girls with a breast
cancer family history (BCFH) compared to girls without a
BCFH [20]. In order to identify specific differentially methyl-
ated regions (DMRs) associated with BCA susceptibility, the
current study examined differences in WBC DNA methylation
and hap-ASM between girls with and without a BCFH at 29
candidate loci using massively parallel targeted bis-seq.
Results
Table 1 shows descriptive statistics of LEGACY girls by BCFH
and compares characteristics for those with and without blood
specimens. Girls who provided blood were older (P < 0.0001),
had higher body mass index (BMI; P < 0.0001) and were more
likely to have a BCFH (P = 0.01) than those who did not. There
were no differences in age and BMI by BCFH in girls who gave
blood; 64.7% of the BCFH+ vs. 55.1% of the BCFH- girls were
non-Hispanic White (P = 0.004).
Identification of BCFH-DMRs in ESR1 and SEC16B
The distribution of methylation in the 29 genes by BCFH is
summarized in Table 2. Methylation in ESR1 was, on average,
4.9% (P = 0.003, FDRQ P = 0.08), higher in BCFH+ girls than
BCFH- girls. The median values of average DNA methylation
in ESR1 were 55.0% [interquartile range (IQR) = 21.6%] for
BCFH+ girls and 49.2% (IQR = 25.2%) for BCFH- girls.
(Table 2 and Figure 1). The ESR1 BCFH-DMR is in a down-
stream alternative promoter region, which shows dynamic
chromatin states with histone marks characteristic of poised
chromatin in H1-ESC, HepG2, and NHEK cells but repressed
marks in GM12878 lymphoblastoid cells (Figure 2). The bot-
tom panel of Figure 2 illustrates the variability in methylation
across individual CpG sites for 10 individuals (5 with and 5
without a BCFH) with a shift in the distribution of methylation
toward high net methylation in the BCFH+ group compared to
the girls without a BCFH.














Variable (n = 239) (n = 187) (n = 295) (n = 319)
Age (y) – mean (SD) 10.9 (2.4) 10.5 (2.3) 9.8 (2.4) 9.7 (2.2)
Body Mass Index (kg/m2) –
mean (SD)
18.9 (4.4) 18.7 (4.9) 17.6 (4.3) 17.3 (3.6)
Race/ethnicity n (%) n (%) n (%) n (%)
Non-Hispanic White 155 (64.7) 103 (55.1) 202 (68.5) 186 (58.3)
Hispanic White 57 (24.0) 38 (20.3) 43 (14.6) 55 (17.2)
Black 13 (5.5) 20 (10.7) 16 (5.4) 29 (9.1)
Asian American or
Pacific Islander
12 (5.0) 16 (8.6) 26 (8.8) 39 (12.2)
Mixed race/ethnicity 2 (0.8) 10 (5.3) 8 (2.7) 10 ( 3.1)
Breast Cancer Family
History
None 0 (0.0) 187 (100.0) 0 (0.0) 319 (100)
First-degree 105 (43.9) 0 (0.0) 115 (38.7) 0 (0.0)
Only Second-degree 134 (56.1) 0 (0.0) 180 (61.0) 0 (0.0)
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The mean of methylation in the DNA regions that we que-
ried in SEC16B was 3.6% (P = 0.026, FDRQ P = 0.38) higher in
girls with a BCFH than girls without a BCFH. (Table 2 and
Figure 1). The median methylation levels in SEC16B were
75.1% for BCFH+ girls and 72.8% for BCFH- girls. The statisti-
cally significant associations with ESR1 and SEC16B remained
after adjusting for age, race/ethnicity, and BMI, and further
adjustment by pubertal breast development stage and age at
menarche. Although our main comparisons were between girls
with and without a BCFH, we also calculated a continuous risk
score. The Spearman correlation coefficients between BOADI-
CEA risk score, which includes both family history and any
known BCA genes, and methylation were 0.11 (P = 0.04) for
ESR1 and 0.11 (P = 0.06) for SEC16B, respectively, supporting
the positive overall association with the binary construct of
family history.
The above two BCFH-DMRs showed high inter-individual
variability in methylation levels, while methylation levels in
other genes such as DLGAP2 and CCNL1 showed little varia-
tion, both overall and when compared by BCFH (Figure 1).
Although there was high inter-individual variability of the
methylation of CYP1A1, the levels of methylation did not differ
by BCFH (Figure 1).
BCFH-DMR and hap-ASM in SEC16B suggests a candidate
genetic variant associated with BCA susceptibility
Methylation of the BCFH-DMRs showed high inter-individual
variability (Figure 1). Since our quality control metrics (Sup-
plementary Methods) supported a biological, rather than
technical, explanation for this inter-individual variability in
methylation, we examined whether it might be explained by
hap-ASM. The BCFH-DMR at SEC16B is in the upstream pro-
moter/proximal enhancer region. The region shows dynamic
chromatin marks associated with active enhancer in some cell
types and quiescent chromatin in other cell types (Figure 3).
The amplicon of SEC16B also covered the common SNP,
rs6682862 (Figure 3), and thus could be assessed for hap-ASM
(see Materials and methods). We found strong hap-ASM in
SEC16B in 25 out of 32 heterozygous blood samples with signif-
icant absolute differences between the reference and alternate
allele ranging from 20% to 75% (with bootstrapped Wilcoxon P
value from 0.02 to 6 £ 10¡9). In addition, in all 25 samples
with hap-ASM, the reference allele was methylated while the
alternate allele was unmethylated, indicating hap-ASM and not
genomic imprinting (for which a random, genotype-indepen-
dent, pattern of ASM is expected) as the mechanism (Figure 3).
This conclusion was confirmed by binomial test (binomial test
P value = 3 £ 10¡8). To determine if our findings in WBC are
relevant for breast tissue, we performed bis-seq in 10 normal
breast tissue samples and 10 peripheral blood T lymphocyte
samples (relevant to the host immune response to cancers),
from different individuals, to test for hap-ASM in SEC16B.
Hap-ASM was present in 3 out of 4 heterozygous breast sam-
ples and 2 out 3 heterozygous T cell samples. Although the dif-
ference between alleles was slightly smaller in breast and T cells
than in whole blood WBCs, ranging from 21.4% to 23.7%, the
direction of this difference was consistent across all the tissues
and cell types (Figure 3 and Supplementary Figure 1). In addi-
tion, the net methylation was similar in breast and blood
[70.1% (SD = 8) compared to 70% (SD = 13.9)]. These findings
indicate that the polymorphism in SEC16B has similar effects
in whole blood, T cells, and whole breast tissues.
Methylation of SEC16B was negatively associated with age
(Spearman’s correlation coefficient of -0.13, P = 0.02). In multi-
variable models adjusting for BCFH, age, and rs6682862 geno-
type, only genotype was independently associated with DNA
methylation (P value = 3.5 £ 10¡30, R2 = 0.40), suggesting that
inter-individual variations in SEC16B methylation are mostly
attributable to cis-acting effects of nearby SNPs (Figure 3).
In addition to SEC16B, 9 additional loci with no evidence of
BCFH-DMRs were potentially informative for hap-ASM analy-
sis, namely BRCA1, CCDC85A, CYP1A1, DLGAP2, RAD51L1,
SLC39A14, and ZNF483, and the intergenic regions queried on
chromosome 12 and 16 (referred as Chr12 and Chr16 loci)
(Supplementary Table 2). Bis-seq revealed hap-ASM in
BRCA1 for 19 of 136 heterozygous samples for and in
CCDC85C for 13 of 97 heterozygous samples (Supplementary
Table 2). The finding of hap-ASM in only a subset of heterozy-
gotes is similar to previous observations for other loci [17,21]
and can be explained by extended haplotype effects, in which a
particular combination of more than one SNP is required in cis
to confer significant ASM.
Discussion
Large epidemiologic studies have reported case-control differ-
ence in DNA methylation of WBC DNAs in BCA susceptibility
gene such as BRCA1 in WBC DNAs [9,10]. In this study, we
Table 2. Distribution of methylation levels (percent) in 29 genes by breast cancer
family history (BCFH) in the LEGACY Girls Study.
BCFH+ BCFH-
% Methylation % Methylation
Amplicon No. Median IQR No. Median IQR P value
ADRB1 171 23.0 8.9 142 24.9 10.4 0.125
ARHGEF7 160 36.6 12.6 124 37.1 17.2 0.728
BRCA1 198 83.5 12.7 160 83.3 13.9 0.648
CCDC85A 198 36.6 11.0 157 35.9 11.9 0.463
CCNL1 166 0.1 0.2 131 0.1 0.4 0.799
CDH1 201 5.9 2.7 163 6.1 2.8 0.612
CELF4 198 54.3 15.5 150 51.9 13.5 0.06
Chr 11 169 9.4 11.8 125 9.0 10.4 0.881
Chr 12 201 78.0 6.1 156 77.5 8.2 0.265
Chr 16 209 81.9 11.9 165 81.7 13.2 0.597
Chr 4 161 86.0 14.4 139 85.7 14.6 0.673
CYP1A1 177 44.4 26.9 139 43.4 27.0 0.178
DLGAP2 199 97.2 1.6 163 97.2 1.4 0.498
ESR1 196 55.0 21.6 161 49.2 25.2 0.003
GAB2 168 98.7 3.7 136 99.0 3.2 0.398
GNA12 138 31.6 43.8 105 34.7 32.8 0.646
MCHR2 210 11.2 5.8 165 11.1 5.4 0.98
OBSCN 182 94.2 3.7 148 94.1 3.6 0.696
PCDHGB1 215 38.0 11.0 171 38.8 11.5 0.447
PEX14 191 70.6 14.4 152 72.9 14.8 0.09
RAD23B 134 97.7 2.3 119 98.1 2.5 0.407
RAD51L1 130 98.3 3.6 97 98.7 3.2 0.896
SEC16B 153 75.1 18.9 119 72.8 16.8 0.026
SLC39A14 199 88.4 13.6 162 90.3 11.8 0.238
TCF7L2 169 42.7 29.6 143 45.4 27.9 0.671
TERT 176 97.6 3.8 142 97.8 3.6 0.713
XRCC3 186 78.4 7.2 143 78.7 7.8 0.691
ZFPM2 192 64.5 26.1 152 65.6 20.0 0.088
ZNF483 201 36.3 6.5 157 37.4 7.3 0.384
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compared the methylation status between girls with and with-
out a BCFH to identify specific DMRs associated with BCA sus-
ceptibility. We observed two BCFH DMRs: one region located
in a BCA susceptibility gene, encoding estrogen signaling recep-
tor 1 (ESR1), and one region located in SEC16B, encoding a
transport protein involved in growth and development. While
both of these DMRs showed small but statistically significant
differences in net methylation between girls with and without a
BCFH, these differences were not statistically significant after a
stringent test for false positives. However, because we selected
our list of candidate loci based on a priori criteria, correcting
for false positives may be unnecessarily conservative. In any
event, our findings need to be further tested in replication
studies.
Multiple CpG sites in the amplicon of ESR1 showed consis-
tently higher mean methylation in girls with a BCFH compared
to girls without a BCFH. ESRs are involved in BCA [22] and
studies on BCA cell lines have observed that methylation in a pro-
moter or enhancer of ESR1 is associated with decreased expres-
sion of ERa mRNA and protein [23]. To assess the functional
relevance of methylation in these regions, we first looked at the
correlation between methylation and expression using public
TCGA data. We used MEXPRESS [24] (http://mexpress.be/) to
visualize and examine DNA methylation and expression data
from breast cancers. Methylation measured by Illumina 450K
BeadChips was negatively correlated to gene expression in ESR1;
the Pearson’s correlation coefficients were -0.72 for cg00601836,
-0.34 for cg15626350, and -0.37 for cg04063345. Thus, our
Figure 1. Methylation differences between BCFH+ and BCFH- girls in ESR1, SEC16B, CYP1A1, DLGAP2, and CCNL1. Net CpG methylation values (percent) in BCFH- girls and
BCFH+ girls in 5 gene regions examined in WBC DNA. The red line represents the median methylation. ESR1, SEC16B, and CYP1A1 showed high inter-individual variability
of the methylation level, while the distribution of methylation levels of DLGAP2 and CCNL1 did not. For the CYP1A1, DLGAP2 and CCNL1, there is no difference between
BCFH+ and BCFH- girls, while for ESR1 and SEC16B, there are small but statistically significant differences. Importantly, the range of methylation values for these loci is
wide, suggesting the presence of hap-ASM, in which one local haplotype acts in cis and dictates a low methylation level while another haplotype dictates high
methylation.
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observation of higher methylation in BCFH+ girls should
indicate less expression of ESR1. This observation is consistent
with decreased estrogen signaling associated with increased
ESR1 methylation [25], recruiting the ESR1 protein to AhR
and away from estrogen receptor (ER) target genes, increased
ER degradation, and synthesis of other inhibitory factors [25].
Several SNPs associated with BCA that map to ESR1 have
been reported in GWAS [22,26], and at least 5 SNPs, including
rs9918437, have been found to be related to imbalances in ER
expression [22]. The ESR1 amplicon we studied here is located
within 58 kb of rs9918437. In addition, rs10913469, a GWAS
SNP related to weight and BMI, is located within a 150 kb
window [27,28]. Although there are no informative SNPs in
the ESR1 amplicon and LD data are not available in the 1000
genomes project for the closest common SNPs [29], hap-ASM
might be present, with the hap-ASM index SNP being in LD
with these GWAS SNPs. Using an array-based indirect
approach, Day et al. identified mQTLs in blood lymphocytes at
cg04063345 and cg15626350, which are located in our DMR,
suggesting the presence of hap-ASM in this ESR1 region [30].
In addition, mRNA levels differ between two ESR1 alleles
marked by rs2077647, which is about 1.2 kb 5’ of our amplicon
[31]. Environmental exposures might also contribute to inter-
individual variation in methylation of ESR1 [32,33]. For
Figure 2. BCFH-DMR in an alternate promoter of ESR1. Map and bis-seq showing the BCFH-DMR in an alternate promoter of ESR1. Zoomed-in view of ESR1, showing rel-
evant ENCODE tracks and the amplicons utilized for targeted bis-seq. The BCFH-DMR is located in a downstream ESR1 alternative promoter region and marked by poised
chromatin marks. Graphical representation of bis-seq data for 10 examples of BCFH- girls (left) and BCFH+ girls (right) are shown. Each column represents a consecutive
CpG covered by the amplicon, and each line a unique DNA fragment. White circles are unmethylated CpGs and black circles are methylated CpGs.
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Figure 3. Hap-ASM BCFH-DMR and mQTLs in the promoter of SEC16B. Map and results of bis-seq showing the BCFH-DMR and hap-ASM in the promoter of SEC16B. (A)
Map of SEC16B, showing relevant ENCODE tracks and the amplicons utilized for targeted bis-seq. (B) Bis-seq data showing hap-ASM in the SEC16B promoter region.
Graphical representation of 5 representative whole-blood samples and 1 human normal breast tissue. Additional representations in breast tissues and T cells from periph-
eral blood are shown in the Supplemental figure 1. This region overlaps with the common SNP, rs6682862. Allele A and B are analyzed and represented separately. The
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example, an animal study reported that, in utero, bisphenol A
(BPA) exposure disrupted epigenetic programming of ESR1 in
the brain [32]. DNA methylation alterations in multiple CpG
sites of ESR1 were also reported to be correlated with maternal
smoking during pregnancy and offspring’s methylation pat-
terns in ESR1 [33].
The second BCFH-DM we observed is in SEC16B, a gene
associated with obesity and age at menarche [34,35]. A GWAS
peak SNP associated with menarche and obesity, rs633715, and
one for BMI, rs10913469, are located 85 kb and 25 kb upstream
of the hap-ASM region, respectively [28], although these SNPs
appear to lie just outside of the haplotype block that contains
the hap-ASM index SNP, rs6682862. Interestingly, allele-spe-
cific expression (assessed by eQTL) of SEC16B has been
described in peripheral blood monocytes [36]. The BCFH-
DMR at SEC16B is located in the gene promoter. In the TCGA
data, methylation at cg00647232, which is covered by our bis-
seq amplicon, showed a significant positive correlation to gene
expression (Pearson’s coefficient = 0.09). Our findings of hap-
ASM in this locus in blood and breast tissues, together with
multiple eQTLs associated with SEC16B expression [37], sug-
gest that the small but significant DNA methylation difference
that we have observed in this gene between the BCFH + and
BCFH- girls could manifest functionally as differences in
genetic susceptibility. Although no SNP in SEC16B has yet
been reported as linked to BCA susceptibility, the presence of
eQTLs and hap-ASM in this gene nominates it as a candidate
for further scrutiny, which could be done by genetic fine-
mapping and testing for associations with BCA after taking age
at menarche and BMI into account. Importantly, our breast
tissue samples are from whole excisions and contain not
only epithelial cells but also fibroblasts, endothelial cells, and
adipocytes. Future work on isolated breast epithelial cells, and
on purified adipocytes and fibroblasts, will be necessary to gain
insight on the underlying mechanisms of SEC16B associated
susceptibility. The analysis of hap-ASM in adipocytes could be
particularly important since this gene has been associated with
obesity by GWAS and, indeed, the effect on breast cancer risk
may be biologically linked to adiposity [38]. In fact, we directly
examined methylation at SEC16B locus in adipose tissue using
ENCODE whole-genome bisulfite sequencing generated by
the ENCODE consortium (https://www.encodeproject.org/).
Although only 3 samples were sequenced, the high inter-
individual variability in the methylation level and pattern is
suggestive of hap-ASM. Regarding the functional relevance of
hap-ASM in T cells, results from recent clinical trials using
immune checkpoint inhibitors in multiple cancers, including
BCA [39], support an active role of immune infiltration in
cancers.
We downloaded TCGA public data from the cancer browser
(https://genome-cancer.ucsc.edu/). We compared methylation
between the 22 BCA bearing mutation in BRCA1 or BRCA2
and 630 cancers without any of these mutations. For ESR1, we
did not observe a significant effect of BRCA1/2 mutations on
methylation (difference between mutated vs. non-mutated can-
cers = ¡2.1%, P = 0.2). In addition, this non-significant trend
was in the opposite direction to the one observed in BCFH+ vs.
BCFH- comparison, suggesting that our findings for ESR1 is
unlikely due to a higher prevalence of BRCA1/2 mutation in
BCFH + compared to BCFH- girls. For SEC16B, we observed a
non-significant relative hypermethylation in the BRCA1/2
mutated vs. non mutated cancers (7%, P = 0.12). Although this
hypermethylation was not significant, we cannot exclude that
part of the difference that we observed in BCFH+ vs. BCFH-
comparison is driven by the unbalanced distribution of
BRCA1/2 mutations in our groups. However, although we
expect a higher prevalence of these mutations in BCFH+ girls,
the low prevalence of BRCA1 and BRCA2 in the general popu-
lation (1.56% and 1.87% in TCGA data, respectively) suggests,
if present, a modest confounding effect. We acknowledge that
future work should assess the effect of BRCA1/2 mutations on
net methylation difference as well as on the presence and
strength of hap-ASM in SEC16B.
We observed possible hap-ASM in BRCA1 and CCDC85C;
however, since the magnitude of the hap-ASM was variable
and the proportion of samples showing it was low for these
genes, further exploration of these loci is required. Other loci
that showed a wide range of methylation but lacked informative
SNPs in the amplicons (e.g., ESR1) will also need to be exam-
ined for possible hap-ASM using additional amplicons. We
believe that a non-negligible part of differentially methylated
loci identified by large sample size case/control methylation
studies (EWAS) are in fact hap-ASM dictated by disease-associ-
ated SNPs, the difference between case and control reflecting
the unbalanced distribution in cases vs. controls of these disease
associated SNPs [21]. Therefore, mapping hap-ASM can help
prioritizing disease-associated SNPs and unravel biological
pathways disrupted by genetic variants.
A key strength of our study is that it is enriched with girls
with a BCFH, permitting identification of genes or loci for which
dysregulated methylation might partially explain family cluster-
ing of cancer. Using bis-seq, we assessed ASM and examined the
potential genetic effect on the BCFH-DM. Advantages of the
bis-seq method that we used here are the ability to examine
methylation across multiple CpGs and to separate the sequenc-
ing reads by allele. An important limitation with using WBC
DNA is that both net methylation and hap-ASM can be tissue-
and cell type-specific [17]. However, an advantage of using
SNP dictates methylation level with the alternate allele (allele B) being significantly hypomethylated compared to the reference allele (allele A), suggesting the presence
of hap-ASM in 25 out of 32 heterozygous samples. The low methylated allele is significantly biased toward allele B (P = 3 £ 10¡08, using binomial test), which ruled out
imprinting. For each heterozygous sample, Wilcoxon P value and methylation difference between alleles were calculated by bootstrapping (1,000 sampling of 50 reads
per allele) and are indicated only for significant hap-ASM defined as difference in percentage methylation >20%, >3 ASM CpGs, and P < 0.05. One representative ran-
dom sample of each allele (20 reads per allele) is shown. ΔMeth (difference in percentage of methylation between alleles in heterozygous samples) and Wilcoxon P values
are from bootstrapping.  indicates the position of the index SNP which overlap with a CpG site, which is, therefore, always unmethylated on allele B. (C) CpG methylation
values (percent) by genotypes in BCFH- girls (Up) and BCFH+ girls (Bottom). The red line represents the median methylation. Methylation and genotype significantly cor-
relate in both groups supporting mQTL/hap-ASM. Girls with the AA genotype had the highest methylation levels, while girls with BB genotype had lowest methylation
levels. The number of samples for each genotype and the distribution (%) is indicated below each graph.
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WBC DNA is that it can be collected repeatedly, particularly
across development. For example, using a repeated sample
design of 51 children before and after puberty, Almstrup et al.
[40] identified methylation changes associated with puberty in a
total of 457 CpG sites, including 5 CpG sites located in the pro-
moter of thyroid receptor-interacting protein (TRIP6), a gene
involved in cell signaling, cell invasiveness and transcriptional
activation. We did not examine this gene here but plan on
examining repeated measures of DNA methylation pre- and
post-puberty in the LEGACY girls. Other types of regulatory
sequences will also need to be examined; for example, higher
methylation variability in dysregulation in DNA methylation of
BCA genes, such as ATM in WBC DNA was observed in intra-
genic repetitive elements rather than in promoter regions [41].
Although we selected the list of candidate genes based on a pri-
ori considerations including pilot data using genome-wide DNA
methylation platform, if we were to conservatively divide the P
value by the number of tests we conducted, our results for
SEC16B may be due to chance. Thus, although our findings sug-
gest a potential role for mQTLs in genes important to BCA,
they need to be replicated in independent series. Here, we exam-
ined an a priori list of targeted genes based on criteria described
in the methods. Our results suggest that larger scale of screening
of mQTLs/hap-ASM may be fruitful for characterizing differen-
ces that may be evident early in life, and may be partly geneti-
cally determined, in individuals with a cancer family history.
We recognize that the abundance of specific cell subtypes,
which may have different levels of methylation in the genes of
interest, likely impacts our results. However, we evaluated dif-
ferences in methylation related to BCFH and, even if differen-
ces are partially the result of large changes in methylation of a
small subset of cells, we have no reason to expect that these
subsets differ by BCFH. We examined whether the ESR1 region
where we found differences in methylation could be explained
by cell type differences by examining publically available meth-
ylation data (GEO accession: GSE35069) and did not find any
differences in methylation by cell type, including WBC, periph-
eral blood mononuclear cells, monocytes, and neutrophils [42].
Our findings, if replicated, suggest that methylation in BCA
related genes may differ between individuals with and without
a BCFH, in part due to genetic-epigenetic interactions. To
understand whether genetic or environmental factors early in
life may be associated with changes in DNA methylation, pro-
spective studies are needed that measure within-individual
changes in exposures and DNA methylation over time and that




Participants were girls ages 6–13 years participating in the LEG-
ACY Girls Study, which is a multicenter prospective study follow-
ing 1,040 girls and their participating parent or guardian, with
data collection every six months on clinical and epidemiological
factors (for details see www.legacygirlsstudy.org and [43,44]).
Girls were invited to provide biospecimens, including blood at
baseline and at follow-up visits. Almost half of the girls have a
BCFH, defined as at least one first- or second-degree relative diag-
nosed with BCA. Forty-one percent of the girls (n = 426) pro-
vided blood at baseline. We also collected demographic and
epidemiological information, including family history of breast
cancer, by interviews, and anthropometric measurements (height
and weight) using standardized protocols. Because we have
already reported differences between blood and saliva DNA
methylation [45], we did not include girls who only provided
saliva at baseline (n = 509). All participating institutions obtained
Institutional Review Board approval to conduct the study.
Bis-seq for DNA methylation analysis
The selection criteria we used to develop a panel of DNA meth-
ylation levels in 29 candidate loci was based on published
genetic or epigenetic association, with at least one or more of
the following categories: (i) genes that are associated with
GWAS SNPs or mutations related to BCA risk [46,47]; (ii)
genes related to age at menarche from GWAS [34]; (iii) genes
related to growth and development from GWAS [48] or EWAS
[49]; (iv) genes involved in DNA recombination and repair
(http://sciencepark.mdanderson.org/labs/wood/dna_repair_
genes.html); and (v) the top 8 candidate CpG sites that showed
evidence of methylation changes between girls with and with-
out a BCFH in our exploratory genome-wide DNA methylation
profiling from pilot work in 48 girls, but outside the above
selection criteria (Supplementary Table 1). For each locus, we
selected the bis-seq primer locations based on the chromatin
states defined by Ernst et al. [50] and available in the UCSC
human genome browser [51]. We focused on active promoters
and enhancers, insulators, and poised chromatin, since these
regions are implicated in gene regulation in cancers and are
often enriched in diseaseassociated DMRs and mQTLs/hap-
ASM [17,52]. In addition, we covered a few loci with repressed
chromatin or transcription associated chromatin states. When
indicated, annotation of GWAS peaks was performed using the
NHGRI-EBI catalog [27] and literature searches for smaller-
scale genetic association studies.
We examined DNA methylation for an amplicon (approxi-
mately 200–300 bp) for these 29 selected loci using massive
parallel targeted bis-seq on genomic DNA from the WBC sam-
ples, as described [17]. Unlike Methylation BeadChips, bis-
seq provides a qualitative and quantitative approach to identify
5-methylcytosine at single base-pair resolution over multiple
contiguous CpG sites, as well as the potential to assess methyla-
tion level after separation by alleles [17,53]. We also measured
DNA from breast normal tissues in 10 women: 8 from adjacent
non tumor tissues, 1 from breast reduction, and 1 from benign
tumor and 10 T cells from adults without BCA [17]. Details of
the DNA methylation measurements are in the Supplementary
Methods. We calculated methylation percentages by averaging
across all CpGs in the amplicon.
Statistical methods
Identification of differentially methylated regions (DMRs)
associated with BCFH
To assess BCFH-DMRs, we compared average methylation dif-
ference for each amplicon between girls with and without a
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BCFH using the Wilcoxon rank-sum test. We calculated false
discovery rate (FDR) q value using PROC MULTTEST proce-
dure. For each DMR, we carried out a multivariable analysis
using linear regression models with DNA methylation percent-
age as the outcome, and categorical variables for BCFH, race/
ethnicity, and pubertal development, and continuous variables
for age and body mass index [BMI; weight (kg)/height squared
(m)] as covariates. Using the Breast and Ovarian Analysis of
Disease Incidence and Carrier Estimation Algorithm (BOADI-
CEA) risk model [54], we previously had estimated the absolute
risk based on family pedigree information for each girl [55]. We
also examined the correlation between BCFH-DMRs and the
BOADICEA risk model. In addition, for loci with available
genotyping data, SNP genotype was also included in the model
(see genotyping method below). We set the significance level
2-sided P value<0.05.
Identification of hap-ASM
To identify hap-ASM we used an approach similar to that in
Do et al. [17] Genotype calling for informative SNPs in the bis-
seq amplicons was carried out after alignment of the sequenc-
ing reads. Overall, 10 amplicons covered at least one informa-
tive SNP and were included for hap-ASM analysis
(Supplementary Table 2). Details of assessing hap-ASM are
provided in the Supplementary Methods. All analyses were
performed with SAS software 9.4 (SAS Institute, Cary, NC) and
R.3.10.
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